Literature DB >> 28011608

Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease.

Won-Jung Koh1, Byeong-Ho Jeong1, Su-Young Kim1, Kyeongman Jeon1, Kyoung Un Park2, Byung Woo Jhun1, Hyun Lee1, Hye Yun Park1, Dae Hun Kim1, Hee Jae Huh3, Chang-Seok Ki3, Nam Yong Lee3, Hong Kwan Kim4, Yong Soo Choi4, Jhingook Kim4, Seung-Heon Lee5, Chang Ki Kim5, Sung Jae Shin6, Charles L Daley7, Hojoong Kim1, O Jung Kwon1.   

Abstract

BACKGROUND: Treatment outcomes of patients with Mycobacterium abscessus subspecies abscessus lung disease are poor, and the microbial characteristics associated with treatment outcomes have not been studied systematically. The purpose of this study was to identify associations between microbial characteristics and treatment outcomes in patients with M. abscessus lung disease.
METHODS: Sixty-seven consecutive patients with M. abscessus lung disease undergoing antibiotic treatment for ≥12 months between January 2002 and December 2012 were included. Morphotypic and genetic analyses were performed on isolates from 44 patients.
RESULTS: Final sputum conversion to culture negative occurred in 34 (51%) patients. Compared to isolates from 24 patients with persistently positive cultures, pretreatment isolates from 20 patients with final negative conversion were more likely to exhibit smooth colonies (9/20, 45% vs 2/24, 8%; P = .020), susceptibility to clarithromycin (7/20, 35% vs 1/24, 4%; P = .015), and be of the C28 sequevar with regard to the erm(41) gene (6/20, 30% vs 1/24, 4%; P = .035). Mycobacterium abscessus lung disease recurred in 5 (15%) patients after successful completion of antibiotic therapy. Genotypic analysis revealed that most episodes (22/24, 92%) of persistently positive cultures during antibiotic treatment and all cases of microbiologic recurrence after treatment completion were caused by different M. abscessus genotypes within a patient.
CONCLUSIONS: Precise identification to the subspecies level and analysis of mycobacterial characteristics could help predict treatment outcomes in patients with M. abscessus lung disease. Treatment failures and recurrences are frequently associated with multiple genotypes, suggesting reinfection. CLINICAL TRIALS REGISTRATION: NCT00970801.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990Mycobacterium abscessuszzm321990; lung disease.; macrolides; nontuberculous mycobacteria

Mesh:

Substances:

Year:  2016        PMID: 28011608     DOI: 10.1093/cid/ciw724

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  63 in total

1.  Whole-Genome Sequencing for Predicting Clarithromycin Resistance in Mycobacterium abscessus.

Authors:  Samuel Lipworth; Natasha Hough; Laura Leach; Marcus Morgan; Katie Jeffery; Monique Andersson; Esther Robinson; E Grace Smith; Derrick Crook; Tim Peto; Timothy Walker
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

2.  Comparing the Utilities of Different Multilocus Sequence Typing Schemes for Identifying Outbreak Strains of Mycobacterium abscessus subsp. massiliense.

Authors:  Aristine Cheng; Hsin-Yun Sun; Yi-Tzu Tsai; Shu-Yuan Chang; Un-In Wu; Po-Ren Hsueh; Wang-Huei Sheng; Yee-Chun Chen; Shan-Chwen Chang
Journal:  J Clin Microbiol       Date:  2019-12-23       Impact factor: 5.948

3.  Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease.

Authors:  Hayoung Choi; Su-Young Kim; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Seung-Heon Lee; Soyoun Shin; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

4.  Diversity of Nontuberculous Mycobacteria in Kuwait: Rapid Identification and Differentiation of Mycobacterium Species by Multiplex PCR, INNO-LiPA Mycobacteria v2 Assay and PCR Sequencing of rDNA.

Authors:  Suhail Ahmad; Eiman Mokaddas
Journal:  Med Princ Pract       Date:  2019-02-14       Impact factor: 1.927

5.  Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease.

Authors:  Bumhee Yang; Byung Woo Jhun; Seong Mi Moon; Hyun Lee; Hye Yun Park; Kyeongman Jeon; Dae Hun Kim; Su-Young Kim; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

6.  In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.

Authors:  Dae Hun Kim; Byung Woo Jhun; Seong Mi Moon; Su-Young Kim; Kyeongman Jeon; O Jung Kwon; Hee Jae Huh; Nam Yong Lee; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

7.  Biofilms of Mycobacterium abscessus Complex Can Be Sensitized to Antibiotics by Disaggregation and Oxygenation.

Authors:  Mette Kolpen; Peter Østrup Jensen; Tavs Qvist; Kasper Nørskov Kragh; Cecillie Ravnholt; Blaine Gabriel Fritz; Ulla Rydahl Johansen; Thomas Bjarnsholt; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

8.  GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance.

Authors:  Hee Jae Huh; Su-Young Kim; Hyang Jin Shim; Dae Hun Kim; In Young Yoo; On-Kyun Kang; Chang-Seok Ki; So Youn Shin; Byung Woo Jhun; Sung Jae Shin; Charles L Daley; Won-Jung Koh; Nam Yong Lee
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

9.  No Amikacin, No Problem: a Successful Treatment Approach for Pediatric Otomastoiditis Due to Amikacin-Resistant Mycobacterium abscessus.

Authors:  William J Richter; Keira A Cohen
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

10.  Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease.

Authors:  Byung Woo Jhun; Bumhee Yang; Seong Mi Moon; Hyun Lee; Hye Yun Park; Kyeongman Jeon; O Jung Kwon; Jungmin Ahn; Il Joon Moon; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.